Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Palese

Showing results (271-280 of 291) with videos related to

Pageof 30
Sort By:
Vaccine|March 4, 2025
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in BrazilÉrique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, et al.
Frontiers in Immunology|June 14, 2024
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individualsAlejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, Ruth Lizzeth Madera-Sandoval, et al.
Vaccine|June 30, 2026
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adultsSean T H Liu, Irene González-Domínguez, Amparo Martínez-Pérez, et al.
Immunity|January 21, 2016
Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus InfectionNicholas S Heaton, Natasha Moshkina, Romain Fenouil, et al.
Immunity|October 23, 2020
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza VirusesJenna J Guthmiller, Linda Yu-Ling Lan, Monica L Fernández-Quintero, et al.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Nature|December 23, 2021
Broadly neutralizing antibodies target a haemagglutinin anchor epitopeJenna J Guthmiller, Julianna Han, Henry A Utset, et al.
Vaccine|November 11, 2024
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in MexicoConstantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
NPJ Vaccines|May 10, 2023
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in MexicoSamuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, et al.
Pageof 30

Showing results (271-280 of 291) with videos related to

Sort By:
Pageof 30
Vaccine|March 4, 2025
Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Results of a randomized vaccine-controlled phase I ADAPTCOV trial in BrazilÉrique José Farias Peixoto de Miranda, Rodrigo T Calado, Fernanda Castro Boulos, et al.
Frontiers in Immunology|June 14, 2024
Newcastle disease virus vector-based SARS-CoV-2 vaccine candidate AVX/COVID-12 activates T cells and is recognized by antibodies from COVID-19 patients and vaccinated individualsAlejandro Torres-Flores, Luis Alberto Ontiveros-Padilla, Ruth Lizzeth Madera-Sandoval, et al.
Vaccine|June 30, 2026
Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adultsSean T H Liu, Irene González-Domínguez, Amparo Martínez-Pérez, et al.
Immunity|January 21, 2016
Targeting Viral Proteostasis Limits Influenza Virus, HIV, and Dengue Virus InfectionNicholas S Heaton, Natasha Moshkina, Romain Fenouil, et al.
Immunity|October 23, 2020
Polyreactive Broadly Neutralizing B cells Are Selected to Provide Defense against Pandemic Threat Influenza VirusesJenna J Guthmiller, Linda Yu-Ling Lan, Monica L Fernández-Quintero, et al.
Nature Medicine|December 8, 2020
A chimeric hemagglutinin-based universal influenza virus vaccine approach induces broad and long-lasting immunity in a randomized, placebo-controlled phase I trialRaffael Nachbagauer, Jodi Feser, Abdollah Naficy, et al.
Nature|December 23, 2021
Broadly neutralizing antibodies target a haemagglutinin anchor epitopeJenna J Guthmiller, Julianna Han, Henry A Utset, et al.
Vaccine|November 11, 2024
Phase II study on the safety and immunogenicity of single-dose intramuscular or intranasal administration of the AVX/COVID-12 "Patria" recombinant Newcastle disease virus vaccine as a heterologous booster against COVID-19 in MexicoConstantino López-Macías, Martha Torres, Brenda Armenta-Copca, et al.
Vaccine|May 16, 2022
Safety and immunogenicity of an egg-based inactivated Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomized, placebo-controlled, phase 1/2 trial in VietnamAnh Duc Dang, Thiem Dinh Vu, Ha Hai Vu, et al.
NPJ Vaccines|May 10, 2023
Interim safety and immunogenicity results from an NDV-based COVID-19 vaccine phase I trial in MexicoSamuel Ponce-de-León, Martha Torres, Luis Enrique Soto-Ramírez, et al.
Pageof 30